Cargando…
The future of targeted kinase inhibitors in melanoma
Melanoma is a cancer of the pigment-producing cells of the body and its incidence is rising. Targeted inhibitors that act against kinases in the MAPK pathway are approved for BRAF-mutant metastatic cutaneous melanoma and increase patients’ survival. Response to these therapies is limited by drug res...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187889/ https://www.ncbi.nlm.nih.gov/pubmed/35513054 http://dx.doi.org/10.1016/j.pharmthera.2022.108200 |